MCID: SRS001
MIFTS: 55

Serous Cystadenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Serous Cystadenocarcinoma

MalaCards integrated aliases for Serous Cystadenocarcinoma:

Name: Serous Cystadenocarcinoma 12 15
Cystadenocarcinoma, Serous 45 74
Serous Adenocarcinoma 12 17
Cystadenocarcinoma Serous 56
Serous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3114
MeSH 45 D018284
NCIt 51 C3778 C40101
SNOMED-CT 69 90725004
UMLS 74 C0206701

Summaries for Serous Cystadenocarcinoma

Disease Ontology : 12 A cystadenocarcinoma that derives from epithelial cells originating in glandular tissue forming serous lesions.

MalaCards based summary : Serous Cystadenocarcinoma, also known as cystadenocarcinoma, serous, is related to uterine corpus serous adenocarcinoma and ovarian serous cystadenocarcinoma. An important gene associated with Serous Cystadenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Innate Immune System and GPCR Pathway. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary, pancreas and bone, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 77 Serous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma... more...

Related Diseases for Serous Cystadenocarcinoma

Diseases related to Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 273)
# Related Disease Score Top Affiliating Genes
1 uterine corpus serous adenocarcinoma 33.3 ERBB2 FBXW7 PIK3CA PPP2R1A TP53
2 ovarian serous cystadenocarcinoma 32.0 AKT1 B2M ERBB2 FBXW7 HRAS MUC16
3 primary peritoneal carcinoma 31.2 ERBB2 MUC16 PGR TP53 VEGFA
4 cervical adenocarcinoma 30.5 ERBB2 PGR TP53
5 adenocarcinoma 30.5 AKT1 ERBB2 HRAS PIK3CA TP53 VEGFA
6 ovarian clear cell carcinoma 30.5 PIK3CA PPP2R1A TP53
7 in situ carcinoma 30.2 ERBB2 PGR TP53
8 testicular germ cell tumor 30.0 ALPP HRAS TP53
9 transitional cell carcinoma 29.9 ERBB2 HRAS TP53
10 carcinosarcoma 29.8 ERBB2 HRAS PGR PIK3CA TP53
11 melanoma, cutaneous malignant 1 29.8 HRAS NRAS PIK3CA TP53
12 wilms tumor 1 29.7 ERBB2 FBXW7 PGR TP53
13 cystadenocarcinoma 29.6 AKT1 ERBB2 FBXW7 HRAS MUC16 PGR
14 endometriosis 29.6 ESR2 PGR VEGFA
15 fallopian tube carcinoma 29.5 ERBB2 PGR TP53 VEGFA
16 adenomyosis 29.4 MMP2 PGR VEGFA
17 pancreatic cancer 29.2 AKT1 ERBB2 HRAS PIK3CA TP53 VEGFA
18 lymphangioleiomyomatosis 29.1 MMP14 MMP2 PGR
19 ovarian cancer 1 28.9 AKT1 ERBB2 MMP2 PIK3CA TP53 VEGFA
20 endometrial adenocarcinoma 28.6 AKT1 ERBB2 ESR2 PGR TP53 VEGFA
21 uterine carcinosarcoma 28.5 ERBB2 ESR2 FBXW7 HRAS PGR PIK3CA
22 squamous cell carcinoma 28.2 AKT1 ERBB2 HRAS MMP2 PIK3CA TP53
23 endometrial cancer 27.9 AKT1 ERBB2 ESR2 HRAS MMP2 MUC16
24 lung cancer susceptibility 3 27.5 AKT1 ERBB2 ESR2 HRAS MMP2 NRAS
25 ovarian cancer 27.0 AKT1 ALPP ERBB2 ESR2 MMP14 MMP2
26 colorectal cancer 27.0 AKT1 ERBB2 ESR2 FBXW7 HRAS MMP14
27 breast cancer 26.8 AKT1 ERBB2 ESR2 FBXW7 HRAS MMP14
28 pancreatic serous cystadenocarcinoma 12.7
29 peritoneal serous adenocarcinoma 12.3
30 fallopian tube serous adenocarcinoma 12.3
31 ovary serous adenocarcinoma 12.2
32 uterine ligament serous adenocarcinoma 12.2
33 cervical serous adenocarcinoma 12.2
34 ovarian serous carcinoma 11.6
35 papillary serous adenocarcinoma 11.3
36 ovarian cystadenocarcinoma 10.7
37 ethmoid sinus adenocarcinoma 10.5 HRAS PIK3CA
38 aggressive digital papillary adenocarcinoma 10.5 HRAS PIK3CA
39 non-proliferative fibrocystic change of the breast 10.5 ERBB2 TP53
40 melanomatosis 10.4 HRAS NRAS
41 olfactory groove meningioma 10.4 PGR TP53
42 adult hepatocellular carcinoma 10.4 PIK3CA TP53
43 giant congenital nevus 10.4 HRAS NRAS
44 malignant spiradenoma 10.4 PIK3CA TP53
45 adenoid basal cell carcinoma 10.4 B2M PGR
46 endometrium carcinoma in situ 10.4 PGR TP53
47 apocrine adenoma 10.4 HRAS PIK3CA
48 gastric papillary adenocarcinoma 10.4 ERBB2 TP53
49 prostate adenoid cystic carcinoma 10.3 HRAS PIK3CA
50 apocrine adenocarcinoma 10.3 ERBB2 PGR

Graphical network of the top 20 diseases related to Serous Cystadenocarcinoma:



Diseases related to Serous Cystadenocarcinoma

Symptoms & Phenotypes for Serous Cystadenocarcinoma

GenomeRNAi Phenotypes related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.86 HRAS
2 Decreased viability GR00221-A-1 9.86 AKT1 HRAS NRAS
3 Decreased viability GR00221-A-2 9.86 AKT1 HRAS
4 Decreased viability GR00221-A-3 9.86 AKT1 ERBB2 HRAS NRAS
5 Decreased viability GR00221-A-4 9.86 AKT1 ERBB2
6 Decreased viability GR00402-S-2 9.86 AKT1 ERBB2 HRAS NRAS
7 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.63 ALPP ERBB2 HRAS NRAS PPP2R1A VEGFA
8 Increased cell death HMECs cells GR00103-A-0 9.02 FBXW7 PGR PIK3CA PPP2R1A TP53

MGI Mouse Phenotypes related to Serous Cystadenocarcinoma:

47 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.42 AKT1 B2M ERBB2 ESR2 FBXW7 HRAS
2 homeostasis/metabolism MP:0005376 10.39 AKT1 B2M ERBB2 ESR2 FBXW7 HRAS
3 growth/size/body region MP:0005378 10.38 AKT1 B2M ERBB2 ESR2 FBXW7 HRAS
4 behavior/neurological MP:0005386 10.36 AKT1 ERBB2 ESR2 HRAS MMP14 NRAS
5 cellular MP:0005384 10.35 AKT1 B2M ERBB2 ESR2 FBXW7 MMP14
6 endocrine/exocrine gland MP:0005379 10.35 AKT1 B2M ERBB2 ESR2 FBXW7 HRAS
7 mortality/aging MP:0010768 10.32 AKT1 B2M ERBB2 ESR2 FBXW7 HRAS
8 integument MP:0010771 10.3 AKT1 B2M ERBB2 ESR2 FBXW7 HRAS
9 immune system MP:0005387 10.28 AKT1 B2M ESR2 FBXW7 MMP14 MMP2
10 hematopoietic system MP:0005397 10.26 AKT1 B2M ESR2 FBXW7 MMP14 MMP2
11 neoplasm MP:0002006 10.25 AKT1 B2M ERBB2 ESR2 FBXW7 HRAS
12 digestive/alimentary MP:0005381 10.24 B2M ERBB2 ESR2 FBXW7 HRAS MMP14
13 embryo MP:0005380 10.24 AKT1 ERBB2 FBXW7 MMP14 NRAS PGR
14 craniofacial MP:0005382 10.2 ERBB2 FBXW7 HRAS MMP14 MMP2 NRAS
15 nervous system MP:0003631 10.14 AKT1 B2M ERBB2 ESR2 FBXW7 HRAS
16 muscle MP:0005369 10.11 AKT1 ERBB2 ESR2 MMP14 MMP2 PGR
17 normal MP:0002873 10.1 AKT1 ERBB2 ESR2 FBXW7 HRAS MMP14
18 limbs/digits/tail MP:0005371 10.05 ERBB2 ESR2 MMP14 NRAS PGR TP53
19 liver/biliary system MP:0005370 10.04 AKT1 B2M ESR2 FBXW7 NRAS TP53
20 no phenotypic analysis MP:0003012 9.97 ESR2 HRAS MMP14 NRAS PGR PIK3CA
21 reproductive system MP:0005389 9.91 AKT1 B2M ERBB2 ESR2 MMP14 PGR
22 respiratory system MP:0005388 9.81 AKT1 ERBB2 ESR2 FBXW7 HRAS MMP14
23 skeleton MP:0005390 9.7 AKT1 ERBB2 ESR2 HRAS MMP14 MMP2
24 vision/eye MP:0005391 9.17 FBXW7 MMP14 MMP2 NRAS PIK3CA TP53

Drugs & Therapeutics for Serous Cystadenocarcinoma

Drugs for Serous Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 215)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
2
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
4
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 70789204 6442177
5
Letrozole Approved, Investigational Phase 2, Phase 3,Phase 3,Early Phase 1 112809-51-5 3902
6
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
7
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 46835353 5284616 6436030
8
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
9
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
10
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
11
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
12
Epirubicin Approved Phase 3 56420-45-2 41867
13
Topotecan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 119413-54-6, 123948-87-8 60700
14
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
15
Olaparib Approved Phase 2, Phase 3,Phase 1,Early Phase 1 763113-22-0 23725625
16
Gemcitabine Approved Phase 2, Phase 3,Phase 3,Phase 1 95058-81-4 60750
17
Metformin Approved Phase 2, Phase 3,Phase 1,Early Phase 1 657-24-9 14219 4091
18
Sodium Citrate Approved, Investigational Phase 2, Phase 3 68-04-2
19
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
20
Trametinib Approved Phase 2, Phase 3,Phase 1 871700-17-3 11707110
21
Pembrolizumab Approved Phase 3,Phase 2 1374853-91-4
22
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
23
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
24
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1 56-86-0 33032
25
Calcium Approved, Nutraceutical Phase 2, Phase 3 7440-70-2 271
26
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
27
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Not Applicable 59-30-3 6037
28
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
29
Maleic acid Experimental, Investigational Phase 2, Phase 3,Phase 1 110-17-8, 110-16-7 444972
30
Cediranib Investigational Phase 2, Phase 3,Phase 1 288383-20-0 9933475
31 Paclitaxel poliglumex Experimental, Investigational Phase 3,Phase 1 263351-82-2
32 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
33 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
34 Antimitotic Agents Phase 3,Phase 2,Phase 1
35 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
36 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
37 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
38 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
39 Antifungal Agents Phase 2, Phase 3,Phase 1
40 Estrogens Phase 2, Phase 3,Phase 3,Early Phase 1
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 3,Early Phase 1,Not Applicable
42 Hormone Antagonists Phase 2, Phase 3,Phase 3,Early Phase 1,Not Applicable
43 Aromatase Inhibitors Phase 2, Phase 3,Phase 3,Early Phase 1
44 Estrogen Receptor Antagonists Phase 2, Phase 3,Phase 3,Early Phase 1
45 Estrogen Antagonists Phase 2, Phase 3,Phase 3,Early Phase 1
46 Hormones Phase 2, Phase 3,Phase 3,Early Phase 1,Not Applicable
47 Anti-Infective Agents Phase 2, Phase 3,Phase 3,Phase 1
48 Steroid Synthesis Inhibitors Phase 2, Phase 3,Phase 3,Early Phase 1
49 Immunosuppressive Agents Phase 2, Phase 3,Phase 3,Phase 1
50 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 185)
# Name Status NCT ID Phase Drugs
1 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
2 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
3 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
4 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
5 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
6 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
7 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
8 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
9 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
10 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
11 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
12 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
13 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
14 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
15 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
16 Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
17 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan Hydrochloride;Trametinib
18 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
19 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
20 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
21 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
22 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
23 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
24 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
25 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
26 Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer Not yet recruiting NCT03914612 Phase 3 Carboplatin;Paclitaxel
27 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
28 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
29 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
30 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
31 Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Unknown status NCT02112552 Phase 2 Paclitaxel;Carboplatin
32 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Unknown status NCT02283658 Phase 2 Everolimus;Letrozole
33 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
34 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
35 Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Unknown status NCT00003560 Phase 2 carboplatin;docetaxel
36 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
37 Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2 Paclitaxel;Dexamethasone;Cimetidine;Diphenhydramine
38 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
39 Phase II ABT-888 With Cyclophosphamide Completed NCT01306032 Phase 2 ABT-888;Cyclophosphamide
40 Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer Completed NCT00022620 Phase 2 paclitaxel
41 Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer Completed NCT01583322 Phase 2 vargatef;placebo
42 Uterine Papillary Serous Cancer (UPSC) Trial Completed NCT00147680 Phase 2 Paclitaxel, Carboplatin
43 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
44 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2 Cediranib Maleate
45 Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer Completed NCT00052312 Phase 2 cisplatin;doxorubicin hydrochloride;paclitaxel
46 AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00275028 Phase 2 cediranib maleate
47 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
48 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
49 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
50 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib

Search NIH Clinical Center for Serous Cystadenocarcinoma

Cochrane evidence based reviews: cystadenocarcinoma, serous

Genetic Tests for Serous Cystadenocarcinoma

Anatomical Context for Serous Cystadenocarcinoma

MalaCards organs/tissues related to Serous Cystadenocarcinoma:

42
Ovary, Pancreas, Bone, Lymph Node, Brain, Cervix, Prostate

Publications for Serous Cystadenocarcinoma

Articles related to Serous Cystadenocarcinoma:

(show top 50) (show all 112)
# Title Authors Year
1
MRI Findings of Borderline Retroperitoneal Serous Cystadenocarcinoma. ( 30823957 )
2019
2
A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma. ( 30097905 )
2018
3
Gastric metastasis of ovarian serous cystadenocarcinoma. ( 30233254 )
2018
4
Bilateral Breast and Axillary Lymph Nodes Metastases of an Ovarian Serous Cystadenocarcinoma. ( 30287996 )
2018
5
A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma. ( 30446011 )
2018
6
Two protein-coding genes act as a novel clinical signature to predict prognosis in patients with ovarian serous cystadenocarcinoma. ( 29456732 )
2018
7
Expression of Yes-associated protein 1 and its clinical significance in ovarian serous cystadenocarcinoma. ( 28339095 )
2017
8
Serous cystadenocarcinoma of the spleen. ( 28491168 )
2017
9
High Grade Serous Cystadenocarcinoma of Testis-Case Report of a Rare Ovarian Epithelial Type Tumour. ( 28764180 )
2017
10
EDUCATION AND IMAGING. Hepatobiliary and Pancreatic: Long-term survival of serous cystadenocarcinoma of the pancreas with synchronous liver metastases after aggressive surgical resection. ( 26177796 )
2016
11
Serous Cystadenocarcinoma of the Pancreas: Clinical Features and Management of a Rare Tumor. ( 26998825 )
2016
12
Single nucleotide polymorphisms in glutathione S-transferase P1 and M1 genes and overall survival of patients with ovarian serous cystadenocarcinoma treated with chemotherapy. ( 27073511 )
2016
13
Estimation of Prognostic Marker Genes by Public Microarray Data in Patients with Ovarian Serous Cystadenocarcinoma. ( 27189279 )
2016
14
A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma. ( 27478834 )
2016
15
DNA methylation-regulated microRNA pathways in ovarian serous cystadenocarcinoma: A meta-analysis. ( 27746113 )
2016
16
Serous Cystadenocarcinoma Arising in Presumed Vitelline Duct Remnant: A Case Report and Implications in the Management of Cancer of Unknown Primary. ( 27999702 )
2016
17
Solid variant type of serous cystadenocarcinoma of the pancreas: a case report and review of the literature. ( 25716800 )
2015
18
Synchronous resection of pancreatic serous cystadenocarcinoma and liver metastasis: First reported case and review of literature. ( 26463518 )
2015
19
Serous Neoplasms of the Pancreas: A Clinicopathologic Analysis of 193 Cases and Literature Review With New Insights on Macrocystic and Solid Variants and Critical Reappraisal of So-called "Serous Cystadenocarcinoma". ( 26559376 )
2015
20
Primary Peritoneal Papillary Serous Cystadenocarcinoma - A Rare Malignancy. ( 26713835 )
2015
21
"Sea anemone-like ciliated tumor cells" in a case of serous cystadenocarcinoma of the ovary. ( 26811576 )
2015
22
Serous cystadenocarcinoma of the mesentery in a man: case report and review of literature. ( 24759353 )
2014
23
Neoplasms in the trocar site and peritoneal papillary serous cystadenocarcinoma. ( 25017255 )
2014
24
Paratesticular papillary serous cystadenocarcinoma: a rare entity in Indian population. ( 25308020 )
2014
25
Histological percutaneous diagnosis of stage IV microcystic serous cystadenocarcinoma of the pancreas. ( 23370947 )
2013
26
Ovarian serous cystadenocarcinoma metastasising to the breast. ( 23445161 )
2013
27
Serous cystadenocarcinoma of pancreas. ( 23763806 )
2013
28
IL-17A is elevated in sera of patients with poorly differentiated ovarian papillary serous cystadenocarcinoma. ( 24595078 )
2013
29
Serous cystadenocarcinoma of the pancreas: report of a case and management reflections. ( 22400805 )
2012
30
Peritoneal papillary serous cystadenocarcinoma at a previous laparoscopic trocar site. ( 23040941 )
2012
31
Imaging of pancreatic serous cystadenocarcinoma. ( 22009426 )
2011
32
Pancreatic serous cystadenocarcinoma with invasive growth into the colon and spleen. ( 22066125 )
2011
33
Testicular papillary serous cystadenocarcinoma: a rare case report and review of the literature. ( 22355499 )
2011
34
Serous cystadenocarcinoma of the pancreas with portal thrombosis. ( 20499029 )
2010
35
Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. ( 21266826 )
2010
36
Papillary serous cystadenocarcinoma of the stomach, peritoneum and ovary. ( 20163045 )
2009
37
Collision tumor: serous cystadenocarcinoma and dermoid cyst in the same ovary. ( 18818939 )
2009
38
Pancreatic serous cystadenocarcinoma: a case report and review of the literature. ( 19459016 )
2009
39
Serous cystadenocarcinoma of the ovary in an 11-year-old girl with extensive dissemination and chylothorax: a case report and a brief review of literature. ( 19564753 )
2009
40
Macrocystic serous cystadenocarcinoma of the pancreas: the first report of a new pattern of pancreatic carcinoma. ( 18305183 )
2008
41
Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. ( 18574502 )
2008
42
Serous cystadenocarcinoma of the pancreas with metachronous hepatic metastasis. ( 19060596 )
2008
43
Plasma cell leukemia with ovarian serous cystadenocarcinoma. ( 17883177 )
2007
44
Immunohistochemical identification of primary peritoneal serous cystadenocarcinoma mimicking advanced colorectal carcinoma: a case report. ( 18036260 )
2007
45
[Differential expression of USP2, USP14 and UBE4A between ovarian serous cystadenocarcinoma and adjacent normal tissues]. ( 17553343 )
2007
46
Paratesticular papillary serous cystadenocarcinoma--a case report. ( 16625973 )
2006
47
[Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications]. ( 16793610 )
2006
48
[ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization]. ( 17160949 )
2006
49
Serous cystadenocarcinoma of the pancreas. ( 15982220 )
2005
50
Clinical significance of p21(WAF1/CIP1) and p53 expression in serous cystadenocarcinoma of the ovary. ( 16012716 )
2005

Variations for Serous Cystadenocarcinoma

Expression for Serous Cystadenocarcinoma

Search GEO for disease gene expression data for Serous Cystadenocarcinoma.

Pathways for Serous Cystadenocarcinoma

Pathways related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 132)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 AKT1 B2M ERBB2 FBXW7 HRAS MMP2
2
Show member pathways
13.78 AKT1 ERBB2 ESR2 HRAS MMP2 NRAS
3
Show member pathways
13.78 AKT1 B2M ERBB2 FBXW7 HRAS MUC16
4
Show member pathways
13.61 AKT1 ERBB2 HRAS NRAS PIK3CA PPP2R1A
5
Show member pathways
13.56 AKT1 ERBB2 HRAS MMP2 NRAS PIK3CA
6
Show member pathways
13.51 AKT1 B2M ERBB2 FBXW7 HRAS NRAS
7
Show member pathways
13.39 AKT1 HRAS NRAS PIK3CA PPP2R1A TP53
8
Show member pathways
13.35 AKT1 ERBB2 ESR2 HRAS NRAS PPP2R1A
9
Show member pathways
13.35 AKT1 B2M ERBB2 HRAS MMP2 NRAS
10
Show member pathways
13.04 AKT1 B2M HRAS NRAS PIK3CA TP53
11
Show member pathways
13.03 AKT1 HRAS NRAS PIK3CA TP53 VEGFA
12
Show member pathways
13.02 AKT1 ESR2 HRAS MMP2 NRAS PGR
13
Show member pathways
13.01 AKT1 ERBB2 HRAS NRAS PIK3CA PPP2R1A
14
Show member pathways
12.98 AKT1 ERBB2 HRAS NRAS PIK3CA VEGFA
15
Show member pathways
12.98 AKT1 ERBB2 HRAS NRAS PIK3CA VEGFA
16
Show member pathways
12.95 AKT1 ERBB2 HRAS NRAS PIK3CA TP53
17
Show member pathways
12.93 AKT1 ERBB2 HRAS NRAS PIK3CA
18
Show member pathways
12.88 AKT1 HRAS NRAS PIK3CA TP53
19 12.85 AKT1 ERBB2 HRAS NRAS TP53 VEGFA
20
Show member pathways
12.81 AKT1 HRAS NRAS PIK3CA VEGFA
21
Show member pathways
12.8 AKT1 ERBB2 HRAS NRAS PIK3CA TP53
22
Show member pathways
12.79 AKT1 ERBB2 HRAS NRAS PIK3CA PPP2R1A
23
Show member pathways
12.76 AKT1 HRAS NRAS PPP2R1A TP53
24
Show member pathways
12.75 AKT1 ERBB2 ESR2 HRAS NRAS PGR
25 12.75 AKT1 ERBB2 ESR2 HRAS MMP2 NRAS
26
Show member pathways
12.72 AKT1 HRAS MMP14 MMP2 NRAS PIK3CA
27
Show member pathways
12.68 AKT1 HRAS NRAS PIK3CA VEGFA
28
Show member pathways
12.65 HRAS MMP2 PIK3CA VEGFA
29
Show member pathways
12.63 AKT1 HRAS NRAS PIK3CA
30
Show member pathways
12.62 AKT1 HRAS PIK3CA PPP2R1A
31
Show member pathways
12.62 AKT1 ERBB2 HRAS MMP2 NRAS PIK3CA
32
Show member pathways
12.61 AKT1 ERBB2 HRAS NRAS PIK3CA TP53
33 12.6 ERBB2 HRAS NRAS PIK3CA TP53 VEGFA
34
Show member pathways
12.59 AKT1 ERBB2 HRAS NRAS PIK3CA TP53
35
Show member pathways
12.57 AKT1 ERBB2 ESR2 HRAS NRAS PIK3CA
36
Show member pathways
12.55 AKT1 ERBB2 HRAS MMP2 NRAS PIK3CA
37
Show member pathways
12.54 AKT1 HRAS NRAS PIK3CA
38
Show member pathways
12.53 AKT1 HRAS PIK3CA PPP2R1A TP53
39
Show member pathways
12.52 AKT1 ERBB2 HRAS NRAS PIK3CA TP53
40
Show member pathways
12.51 AKT1 HRAS NRAS PIK3CA
41
Show member pathways
12.51 AKT1 ERBB2 ESR2 HRAS MMP2 NRAS
42
Show member pathways
12.5 AKT1 HRAS NRAS PIK3CA VEGFA
43
Show member pathways
12.48 AKT1 HRAS NRAS PIK3CA
44
Show member pathways
12.48 AKT1 HRAS PIK3CA VEGFA
45
Show member pathways
12.47 AKT1 HRAS NRAS PIK3CA
46
Show member pathways
12.47 AKT1 HRAS PIK3CA TP53
47
Show member pathways
12.46 AKT1 HRAS NRAS PIK3CA
48 12.45 AKT1 HRAS NRAS PIK3CA TP53
49
Show member pathways
12.43 AKT1 PGR PIK3CA PPP2R1A
50
Show member pathways
12.42 AKT1 ERBB2 ESR2 HRAS PIK3CA

GO Terms for Serous Cystadenocarcinoma

Cellular components related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.9 AKT1 ALPP B2M ERBB2 HRAS MMP14
2 mitochondrion GO:0005739 9.5 AKT1 ESR2 FBXW7 MMP2 PGR PPP2R1A
3 membrane GO:0016020 9.47 AKT1 ALPP B2M ERBB2 HRAS MMP14

Biological processes related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.81 MMP14 MMP2 PIK3CA VEGFA
2 positive regulation of gene expression GO:0010628 9.77 AKT1 ERBB2 HRAS TP53 VEGFA
3 lung development GO:0030324 9.73 FBXW7 MMP14 VEGFA
4 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.71 AKT1 PIK3CA VEGFA
5 positive regulation of cell growth GO:0030307 9.7 AKT1 ERBB2 MMP14
6 positive regulation of endothelial cell proliferation GO:0001938 9.67 AKT1 NRAS VEGFA
7 Ras protein signal transduction GO:0007265 9.65 HRAS NRAS TP53
8 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.63 HRAS MUC16 NRAS
9 positive regulation of protein phosphorylation GO:0001934 9.62 AKT1 ERBB2 HRAS VEGFA
10 positive regulation of epithelial cell proliferation GO:0050679 9.61 ERBB2 HRAS VEGFA
11 positive regulation of MAP kinase activity GO:0043406 9.58 ERBB2 HRAS VEGFA
12 negative regulation of macroautophagy GO:0016242 9.57 AKT1 PIK3CA
13 anoikis GO:0043276 9.55 AKT1 PIK3CA
14 negative regulation of Notch signaling pathway GO:0045746 9.43 AKT1 FBXW7 MMP14
15 cytokine-mediated signaling pathway GO:0019221 9.35 AKT1 MMP2 PIK3CA TP53 VEGFA
16 phosphatidylinositol 3-kinase signaling GO:0014065 9.33 AKT1 ERBB2 PIK3CA
17 negative regulation of gene expression GO:0010629 9.02 AKT1 FBXW7 HRAS PGR VEGFA

Molecular functions related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.86 AKT1 ALPP B2M ERBB2 ESR2 FBXW7
2 zinc ion binding GO:0008270 9.63 ALPP ESR2 MMP14 MMP2 PGR TP53
3 identical protein binding GO:0042802 9.23 AKT1 B2M ERBB2 ESR2 FBXW7 PGR

Sources for Serous Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....